FibroGen Announces First Patient Enrolled In Pamrevlumab Phase 3 Clinical Trial In Patients With Duchenne Muscular Dystrophy
SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab orplacebo in combination
Benzinga · 22小时前
FibroGen EPS misses by $0.39, misses on revenue
FibroGen (NASDAQ:FGEN): Q2 GAAP EPS of -$0.95 misses by $0.39. Revenue of $42.89M (-77.6% Y/Y) misses by $5.4M. Press Release
FibroGen Reports Second Quarter 2020 Financial Results
finviz · 5天前
FibroGen Announces New Appointments to its Board of Directors
finviz · 5天前
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
FibroGen to Report Second Quarter 2020 Financial Results
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00
GlobeNewswire · 07/23 11:00
Did Hedge Funds Make The Right Call On FibroGen Inc (FGEN) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of